Extended Data Fig. 3: Impact of treatment on residual tumor cell number in mouse CLEVER preclinical study.
From: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
a, Relative change in residual tumor cell number (RTC) count following 3 weeks or 9 weeks of treatment with the indicated therapies, shown as % change relative to vehicle control. b, Absolute RTC counts following 3 weeks or 9 weeks of treatment with the indicated therapies or vehicle control. Red boxes indicate residual tumor lesions that were classified as recurrent tumors based on progressive increases in tumor size. Purple triangles indicate RTC counts that were statistical outliers. MGRD, mammary gland residual disease. c, Plot of median RFS versus log10 median RTC counts following 3 weeks or 9 weeks of treatment with the indicated therapies or vehicle control shown as a combined cohort. The Pearson correlation coefficient is shown for the combined cohort and tested against the t distribution for estimating a two-sided p value.
